All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): XW003
Therapeutic Area: Endocrinology Product Name: XW003
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: LYFE Capital
Deal Size: $37.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 19, 2021
Details:
Sciwind Biosciences has completed a phase 1 clinical study of XW003, in an overseas clinical site, and phase 2 clinical trials including type II diabetes, obesity and non-alcoholic steatohepatitis (NASH), are expected to be initiated in China in 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dorzagliatin,Empagliflozin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2020
Details:
The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
